CH640415A5 - Therapeutic preparations for the treatment of pain - Google Patents
Therapeutic preparations for the treatment of pain Download PDFInfo
- Publication number
- CH640415A5 CH640415A5 CH341179A CH341179A CH640415A5 CH 640415 A5 CH640415 A5 CH 640415A5 CH 341179 A CH341179 A CH 341179A CH 341179 A CH341179 A CH 341179A CH 640415 A5 CH640415 A5 CH 640415A5
- Authority
- CH
- Switzerland
- Prior art keywords
- alkyl
- trifluoromethyl
- carbon atoms
- formula
- alkoxy
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 20
- 239000001257 hydrogen Substances 0.000 claims abstract description 20
- 239000000460 chlorine Substances 0.000 claims abstract description 14
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 12
- -1 6,7-methylenedioxy Chemical group 0.000 claims abstract description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 10
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 10
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 10
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 10
- 239000011737 fluorine Substances 0.000 claims abstract description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 10
- 125000001424 substituent group Chemical group 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 239000003158 myorelaxant agent Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- OZOMQRBLCMDCEG-VIZOYTHASA-N 1-[(e)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-VIZOYTHASA-N 0.000 claims description 2
- HJICZLOIHNWNNY-UHFFFAOYSA-N 8-(4-fluorophenyl)-5-propan-2-yl-[1,3]dioxolo[4,5-g]quinazolin-6-one Chemical compound N=1C(=O)N(C(C)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(F)C=C1 HJICZLOIHNWNNY-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000001760 anti-analgesic effect Effects 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 125000004799 bromophenyl group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- ODJOWHUVBHWDDK-UHFFFAOYSA-N n-(1-methylindazol-4-yl)-4,5-dihydro-1,3-oxazol-2-amine Chemical compound C1=CC=C2N(C)N=CC2=C1NC1=NCCO1 ODJOWHUVBHWDDK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH341179A CH640415A5 (en) | 1979-04-10 | 1979-04-10 | Therapeutic preparations for the treatment of pain |
| DE19803012837 DE3012837A1 (de) | 1979-04-10 | 1980-04-02 | Analgetische und myotonolytische praeparate |
| GB8011256A GB2047534B (en) | 1979-04-10 | 1980-04-03 | Analgesic and myotonolytic compositions |
| IT48364/80A IT1143133B (it) | 1979-04-10 | 1980-04-08 | Composizioni analgesiche e miotonolitiche |
| PT71066A PT71066A (en) | 1979-04-10 | 1980-04-08 | Process for the preparation of a pharmaceutical composition having analgesic and myotonolytical activity |
| NL8002041A NL8002041A (nl) | 1979-04-10 | 1980-04-08 | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. |
| AU57223/80A AU538643B2 (en) | 1979-04-10 | 1980-04-08 | Quinazolinone/myotonolytic synergystic combination |
| SE8002642A SE445708B (sv) | 1979-04-10 | 1980-04-08 | Farmaceutiskt preparat innehallande ett kinazolinon och 5-klor-4-(2-imidazolin-2-yl-amino)-2,1,3-bensotiadiazol |
| HU80834A HU183119B (en) | 1979-04-10 | 1980-04-08 | Process for producing analgesic and tone-delivering compositions containing quinazoline derivatives and benzothiadiazol derivatives |
| CA000349456A CA1147261A (en) | 1979-04-10 | 1980-04-09 | Analgesic and myotonolytic preparations |
| JP4578480A JPS55141413A (en) | 1979-04-10 | 1980-04-09 | Analgesic and muscle stiffness relaxing medicine |
| AT0191680A AT378916B (de) | 1979-04-10 | 1980-04-09 | Verfahren zur herstellung eines pharmazeutischen kombinationspraeparates |
| NZ193379A NZ193379A (en) | 1979-04-10 | 1980-04-09 | Analgesic and/or myotonolytic compositions based on an analgesically active quinazolinone and a centrally active myotonolytic |
| IE724/80A IE49676B1 (en) | 1979-04-10 | 1980-04-09 | Analgesic and myotonolytic preparations |
| IL59786A IL59786A (en) | 1979-04-10 | 1980-04-09 | Pharmaceutical compositions comprising a quinazolinone derivative and a myotonolytic agent |
| FR8007936A FR2453648A1 (fr) | 1979-04-10 | 1980-04-09 | Nouvelles compositions pharmaceutiques a base d'une quinazolinone exercant une action analgesique et d'un agent myotonolytique |
| PH23883A PH17681A (en) | 1979-04-10 | 1980-04-10 | Analgesic and myotonolytic preparations |
| AR280632A AR228255A1 (es) | 1979-04-10 | 1980-04-10 | Procedimiento para la produccion de una preparacion sinergistica que tiene una actividad analgesica y miotonolitica mejorada |
| ES490453A ES8105148A1 (es) | 1979-04-10 | 1980-04-10 | Un procedimiento para la preparacion de una composicion far-maceutica de quinazolinonas analgesicas |
| US06/407,153 US4442084A (en) | 1979-04-10 | 1982-08-11 | Analgesic and myotonolytic preparations |
| MY127/85A MY8500127A (en) | 1979-04-10 | 1985-12-30 | Analgesic and myotonolytic preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH341179A CH640415A5 (en) | 1979-04-10 | 1979-04-10 | Therapeutic preparations for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH640415A5 true CH640415A5 (en) | 1984-01-13 |
Family
ID=4255400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH341179A CH640415A5 (en) | 1979-04-10 | 1979-04-10 | Therapeutic preparations for the treatment of pain |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS55141413A (cg-RX-API-DMAC7.html) |
| AT (1) | AT378916B (cg-RX-API-DMAC7.html) |
| CH (1) | CH640415A5 (cg-RX-API-DMAC7.html) |
-
1979
- 1979-04-10 CH CH341179A patent/CH640415A5/de not_active IP Right Cessation
-
1980
- 1980-04-09 AT AT0191680A patent/AT378916B/de not_active IP Right Cessation
- 1980-04-09 JP JP4578480A patent/JPS55141413A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AT378916B (de) | 1985-10-25 |
| JPH0132806B2 (cg-RX-API-DMAC7.html) | 1989-07-10 |
| ATA191680A (de) | 1985-03-15 |
| JPS55141413A (en) | 1980-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69432644T2 (de) | Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum | |
| DE69718731T2 (de) | Kombinationstherapie für die Behandlung von Psychosen | |
| DE69114117T2 (de) | Neue Verwendung von Peptidderivat. | |
| DE4341403A1 (de) | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung | |
| DE2946020A1 (de) | Imidazolverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE2708236A1 (de) | 3-aryl-2-oxazolidinone, verfahren zu ihrer herstellung und arzneimittel | |
| DE68925004T2 (de) | Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen. | |
| DE3420193A1 (de) | Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel | |
| DE60030654T2 (de) | Verwendung von Lasofoxifen | |
| DE69005974T2 (de) | Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten. | |
| DE3517820C2 (cg-RX-API-DMAC7.html) | ||
| CA1147261A (en) | Analgesic and myotonolytic preparations | |
| DE69802921T2 (de) | Arzneizubereitungen in trockner form zur oralen verabreichung einer cyclischen quaternären ammoniumverbindung | |
| DE4341402A1 (de) | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung | |
| CH640415A5 (en) | Therapeutic preparations for the treatment of pain | |
| EP0548635B1 (de) | Pharmazeutische Zubereitung von Roxindol oder Carmoxirol mit vorgeqüollener Stärke | |
| DE4338396A1 (de) | N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung | |
| EP0317855A2 (de) | Pharmazeutische Präparate | |
| DE69836095T2 (de) | Eprosartan arginyl-ladungsneutralisationskomplex und verfahren zu dessen herstellung und formulierung | |
| DE3031703C2 (cg-RX-API-DMAC7.html) | ||
| EP0346683A1 (de) | Pyrrolderivate, ihre Herstellung und ihre Verwendung | |
| EP0816358B1 (de) | 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung | |
| DE2817924A1 (de) | 3-(1-piperazinyl)-1,2,4-benzotriazine und ihre n-oxide | |
| AT393625B (de) | Verfahren zur herstellung eines neuen therapeutischen praeparates enthaltend co-dergocrine und einen calciumantagonisten | |
| DE69029814T2 (de) | Inhibitoren der dihydrofolatreduktase von pneumocystis carinii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |